Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Edgewise Therapeutics
< Previous
1
2
Next >
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
April 23, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
April 15, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
March 28, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
March 27, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
March 05, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
February 28, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
February 22, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
February 13, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
January 19, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
January 09, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
December 19, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community
December 18, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
November 30, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 09, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at Upcoming Investor Conferences
November 08, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise to Present Data on EDG-7500 at the American Heart Association’s Scientific Sessions 2023
November 01, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne)
October 26, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present on EDG-5506 for Becker Muscular Dystrophy at the 28th International Annual Congress of the World Muscle Society
September 27, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker)
September 26, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction
September 14, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 10, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
June 26, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the Goldman Sachs Global Healthcare Conference
June 06, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 11, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at Upcoming Investor Conferences
May 02, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD)
March 30, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023
March 21, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference
March 14, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors
March 06, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023
March 01, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.